Martin Fassnacht

Martin Fassnacht is the world's leading authority on adrenocortical carcinoma (ACC), a rare and aggressive endocrine malignancy. He led the FIRM-ACT trial establishing EDP-M (etoposide, doxorubicin, cisplatin plus mitotane) as the standard first-line regimen for advanced ACC, and has chaired the European Network for the Study of Adrenal Tumors (ENSAT) which developed the ACC staging system. His laboratory has characterized molecular drivers of ACC including TP53, CTNNB1, CDK4, and ATRX alterations, and he leads multiple studies evaluating immunotherapy and targeted therapy in ACC.